UC-MSC

Phase 2Cell therapy

AAsia Stem Cell Regenerative Pharmaceutical Co., Ltd.

UC-MSC is one of 110 biologic programs targeting Sepsis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

Hepatitis BActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

CirrhosisActive, not recruiting

SepsisPhase 1/Phase 2

Active, not recruiting

Hepatitis BPreclinical

Active, not recruiting

Chronic Kidney DiseasePhase 1/Phase 2

Active, not recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 2

UC-MSC

AAsia Stem Cell Regenerative Pharmaceutical Co., Ltd.

Phase 2

1 3

Uloric

Takeda

Preclinical

3 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

2 10

Epoetin Beta

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Sepsis

NCT07439848

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )

Unknown status·TTongji Hospital·Phase 1/2·NCT05512988·44 enrolled

Sepsis1 trial

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

Recruiting·PPT. Prodia Stem Cell Indonesia·Phase 1/2·NCT07439848·15 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

Completed·PPeking University People's Hospital·Phase 3·NCT04738981·130 enrolled

Cirrhosis1 trial

Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis

Unknown status·SShandong Qilu Stem Cells Engineering Co., Ltd.·Phase 2·NCT03529136·252 enrolled

Left Ventricular Dysfunction1 trial

UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

Unknown status·SShanghai Life Science & Technology·Phase 1·NCT03902067·40 enrolled

1 more indication

Hepatitis B1 trial

Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis

Unknown status·AAsia Stem Cell Regenerative Pharmaceutical Co., Ltd.·N/A·NCT05106972·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for UC-MSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UC-MSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UC-MSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: AAsia Stem Cell Regenerative Pharmaceutical Co., Ltd.

UC-MSC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Chronic Kidney Disease1 trial

Sepsis1 trial

Efficacy and Safety1 trial

Cirrhosis1 trial

Left Ventricular Dysfunction1 trial

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News